# Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

> **NCT06016634** · PHASE2 · RECRUITING · sponsor: **University of California, Davis** · enrollment: 30 (estimated)

## Conditions studied

- Sickle Cell Disease
- Sickle Cell Anemia
- Osteonecrosis
- Ischemic Necrosis
- Avascular Necrosis

## Interventions

- **DRUG:** Alendronate Sodium

## Key facts

- **NCT ID:** NCT06016634
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06016634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06016634, "Alendronate for Osteonecrosis in Adults With Sickle Cell Disease". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT06016634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*